KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $208.7 million.

  • Regeneron Pharmaceuticals' Non-Current Deffered Revenue rose 1238.56% to $208.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $208.7 million, marking a year-over-year increase of 1238.56%. This contributed to the annual value of $208.7 million for FY2025, which is 1238.56% up from last year.
  • As of Q4 2025, Regeneron Pharmaceuticals' Non-Current Deffered Revenue stood at $208.7 million, which was up 1238.56% from $219.2 million recorded in Q3 2025.
  • Regeneron Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $219.2 million for Q3 2025, and its period low was $27.0 million during Q1 2021.
  • In the last 5 years, Regeneron Pharmaceuticals' Non-Current Deffered Revenue had a median value of $120.8 million in 2023 and averaged $125.7 million.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Non-Current Deffered Revenue crashed by 5902.88% in 2021, and later skyrocketed by 15522.39% in 2023.
  • Regeneron Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $73.3 million in 2021, then decreased by 4.77% to $69.8 million in 2022, then surged by 81.52% to $126.7 million in 2023, then skyrocketed by 46.57% to $185.7 million in 2024, then grew by 12.39% to $208.7 million in 2025.
  • Its last three reported values are $208.7 million in Q4 2025, $219.2 million for Q3 2025, and $206.3 million during Q2 2025.